MedPath

Vaginal Indomethacin for Preterm Labor

Phase 2
Not yet recruiting
Conditions
Obstetric Labor, Premature
Interventions
Registration Number
NCT04404686
Lead Sponsor
Hadassah Medical Organization
Brief Summary

Indometacin is a cyclooxygenase agent from the NSAID family that has been used to treat preterm contractions since the 70's by preventing the synthesis of prostaglandins. It has been shown to be significantly more effective than placebo and postpone labor for 7-10 days, prolong pregnancies above 37 weeks of gestation and reduce numbers of small for gestational age neonates.

Nifedipine is a calcium channel blocker agent that has been shown to reduce rates of labor within 48 hours from treatment.

Previous studies comparing rectal Indometacin to oral nifedipine were inconclusive.

Prostaglandins are synthesized in the uterus and the uterine cervix and therefore local administration of Indometacin may be more effective than other forms of administration, as been shown in a previous study.

In this study we aim to compare vaginal Indometacin administration to a commonly used tocolytic agent, nifedipine.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
300
Inclusion Criteria
  • Singe fetus
  • Gestational age between 24+0/7 and 31+6/7
  • At least one uterine contraction in ten minutes for at least 20 minutes upon tocography admission
  • Cervical parameters: 1 cm dilation or more or 80% cervical effacement or cervical length 20mm or less
Exclusion Criteria
  • Rupture of membranes
  • Vaginal bleeding
  • Cervical dilation ≥5cm
  • Known fetal malformations
  • Fetal heart rate abnormalities
  • Suspected placental abruption of adherent placental syndrome
  • Known sensitivity to one of the drugs used in the study (Indometacin and nifedipine)
  • Maternal hypotension and known aortic or mitral stenosis
  • Presence of cervical cerclage
  • Previous administration of tocolytic drugs in current pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Indomethacin groupIndomethacinGroup of patients receiving Indomethacin for preterm labor treatment.
Nifedipine groupNifedipineGroup of patients receiving Nifedipine for preterm labor treatment.
Primary Outcome Measures
NameTimeMethod
Gestational agethrough study completion, approximately 1 year

Days from last menstrual period

Time to deliverythrough study completion, approximately 1 year

The time from administration of intervention do delivery

Secondary Outcome Measures
NameTimeMethod
Neonatal birth weightthrough study completion, approximately 1 year

birth wight as recorded in chart in grams

Rate of extreme preterm deliveriesthrough study completion, approximately 1 year

Rate of deliveries under 28+0/7 weeks of gestation

Neonatal outcomesthrough study completion, approximately 1 year

neonatal intensive care unit administration rate

Rate of preterm deliveriesthrough study completion, approximately 1 year

Rate of deliveries under 37+0/7 weeks of gestation

neonatal immediate outcomesthrough study completion, approximately 1 year

Neonatal Apgar scores

Rate of remote from term deliveriesthrough study completion, approximately 1 year

Rate of deliveries under 34+0/7 weeks of gestation

Neonatal immediate outcomethrough study completion, approximately 1 year

Neonatal umbilical cord pH levels

© Copyright 2025. All Rights Reserved by MedPath